Clinically different stages of Alzheimer's disease associated by amyloid deposition with [11C]-PIB PET imaging

Journal of Alzheimer's Disease

Volumn 21, Issue 3, 2010, Pages 995-1003

  Hatashita, Shizuo ^a   Yamasaki, Hidetomo ^a  

^a Shonan Atsugi Hospital   (Japan)

Author keywords

Alzheimer's disease; amyloid deposition; dementia; mild cognitive impairment; PET

Indexed keywords

AMYLOID BETA PROTEIN; BENZOTHIAZOLE DERIVATIVE; CARBON 11; N METHYL 2 (4' METHYLAMINOPHENYL) 6 HYDROXYBENZOTHIAZOLE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC IMAGING; DISEASE COURSE; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 77957257228     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100222     Document Type: Article

References (28)

1. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders (IVTR), 4th editiontext revised. Washington D.C.
2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM(1984) Clinical diagnosis of Alzheimer's diseasereport of theNINCDSADRDAwork group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34, 939944. (Pubitemid 14076461)
3. Kazee AM, Eskin TA, Lapham LW, Gabriel KR, McDaniel KD, Hamill RW (1993) Clinicopathologic correlates in Alzheimer disease: Assessment of clinical and pathologic diagnostic criteria. Alzheimer Dis Assoc Disord 7, 152164.
4. Dubois B, Feldman HH, Jacova C, Dekosky ST, BarbergerGateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G,Meguro K, O'Brien J, Pasquier F, Robert P, RossorM, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDSADRDA criteria. Lancet Neurol 6, 734746. (Pubitemid 47058377)
5. Braak H, Braak E (1991) Neuropathological standing of Alzheimerrelated changes. Acta Neuropathol (Berl) 82, 239259.
6. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE (2003) Synthesis and evaluation of [11C]labeled 6substituted 2arylbenzothiazoles as amyloid imaging agents. J Med Chem 46, 27402754. (Pubitemid 36702542)
7. KlunkWE, Engler H,Nordberg A,WangY, Blomqvist G,Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Lngström B (2004) Imaging brain amyloid in Alzheimer' disease with Pittsburgh CompoundB. Ann Neurol 55, 306319. (Pubitemid 38269583)
8. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP,Meltzer CC, DeKosky ST,Mathis CA (2005) Kinetic modeling of amyloid binding in human using PET imaging and Pittsburgh CompoundB. J Cereb Blood Flow Metab 25, 15281547. (Pubitemid 41541962)
9. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST (2008) Postmortem correlates of invivo PiBPET amyloid imaging in a typical case of Alzheimer's disease. Brain 131, 16301645. (Pubitemid 351806448)
10. Folstein MF, Folstein SE, McHugh PR (1975) 'Minimental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189198.
11. Morris JC (1993) The clinical dementia rating (CDR): Current version and scoring rules. Neurology 43, 24122414.
12. Peterson RC, Doody R, Kurz A,Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001) Current concepts in mild cognitive impairment. Arch Neurol 58, 19851992. (Pubitemid 33143977)
13. Wilson AA, Garcia A, Chestakova A, Kung H, Houle S (2004)Arapid onestep radiosynthesis of the-amyloid imaging radiotracer Nmetyl [ 11C]2( 4'methylaminophenyl) 6hydroxybenzothiazole ( [11C]6OHBTA1). J Label Compd Radiopharm 47, 679682.
14. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X,MeltzerCC, SchimmelK, TsopelasND,DeKosky ST, Price JC (2005) Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: A comparative analysis. J Nucl Med 46, 19591972. (Pubitemid 46657441)
15. Rowe CC, NG S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL,Maruff P, Darby D, Smith C,Woodward M, Merory J, TochonDanguy H, O'Keefe G, Klunk WE,Mathis CA, Price JC,Masters CL, Villemagne VL (2007) Imaging betaamyloid burned in aging and dementia. Neurology 68, 17181724. (Pubitemid 46763260)
16. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Lngström B, Nordberg A (2006) Twoyear followup of amyloid deposition in patients with Alzheimer's disease. Brain 129, 28562866. (Pubitemid 44684508)
17. Ingelsson M, Fukumoto H, Newell KL, Growdon JH, HedleyWhyte ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC (2004) Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62, 925931. (Pubitemid 38435780)
18. Boyle PA, Wilson RS, Aggarward NT, Tang Y, Bennett DA (2006) Mild cognitive impairment: Risk of Alzheimer disease and rate of cognitive decline. Neurology 67, 441445. (Pubitemid 44214968)
19. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Lngström B, Nordberg A (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29, 14561465.
20. Okello A, Koivumen J, Edison P, Archer HA, Turkheimer FE, Ngren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: An [11C]PIB PET study. Neurology 73, 754760.
21. Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, Aizenstein HJ, Cohen AD, Weissfeld LA, Mathis CA, Klunk WE, DeKosky ST (2009) Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 65, 557568.
22. Peterson RC, Parisi JE, Dickson DW, Snitz BE, James JA, Lopez OL, Aizenstein HJ, Cohen AD, Weissfeld LA, Mathis CA,KlunkWE,DeKosky ST (2006) Neuropathologic feature of amnestic mild cognitive impairment. Arch Neurol 63, 665672.
23. Busse A, Angermeyer MC, RiedelHeller SG (2006) Progression of mild cognitive impairment to dementia: A challenge to current thinking. Br J Psychiatry 189, 399404. (Pubitemid 44683170)
24. Alzenstein JH, Nebert RD, Saxon JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Ach Neurol 65, 15091517.
25. Villemage VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, Ackermann U, Cowie TF, Currie J, Chan SG, Jones G, TochonDanguy H, O'Keefe G,Masters CL, Rowe CC (2008) A- deposits in older nondependent individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 46, 16881697.
26. Price JL,Morris JC (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45, 358368. (Pubitemid 29120041)
27. Kiunk WE, Mathis CA (2009) Amyloid imaging and what is "normal" aging. In Imaging the Aging Brain, Jagust W, D'Esposito M, (Eds) New York: Oxford University press, pp. 191-244.
28. Mintun WA, LaRossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC (2006) [11C] PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 67, 446452.